Literature DB >> 2843280

Hepatoma in the noncirrhotic liver.

S R Smalley1, C G Moertel, J F Hilton, L H Weiland, H S Weiand, M A Adson, L J Melton, K Batts.   

Abstract

The pathologic features, clinical presentation and natural history of hepatocellular carcinoma (HCC) developing in the noncirrhotic liver were studied in 61 patients against a background of 63 patients seen concurrently with HCC complicating cirrhosis. Noncirrhotic HCC had a bimodal age distribution, with females predominating the first age-clustering (10-50 years) and males predominating the second age-clustering (50-90 years). Cirrhotic HCC had a unimodal age distribution (40-90 years) with male dominance throughout. Estrogen exposure was noted in 57% of the noncirrhotic HCC women overall and in 80% of those in the younger age-clustering. The majority of noncirrhotic HCC presented with a single hepatic mass or a dominant primary with satellite lesions in contrast to the usual multinodular or diffuse disease seen with cirrhosis. Twenty-nine noncirrhotic patients survived complete resection of disease limited to the liver and exhibited a median survival of 2.7 years with a 5-year survival of 25%. Low histologic grade, minimal necrosis, and the absence of hemoperitoneum, hepatomegaly, and adjacent organ involvement were all favorable prognostic variable. Patients with metastatic or locally unresectable noncirrhotic HCC had a median survival of 9 months, and 24% survived in excess of 2 years. This survival experience is significantly more favorable than cirrhotic HCC patients, who had only a 1.2-month median and a 3% 2-year survival. Low histologic grade, mild mitotic activity and the presence of some fibrosis within the specimen were associated with a favorable outcome in advanced noncirrhotic HCC. The favorable prognosis and heterogeneous composition of the noncirrhotic, when compared to the cirrhotic HCC cohort, may be important considerations in the design and evaluation of future clinical trials.

Entities:  

Mesh:

Year:  1988        PMID: 2843280     DOI: 10.1002/1097-0142(19881001)62:7<1414::aid-cncr2820620729>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

3.  Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.

Authors:  Michele Di Martino; Luca Saba; Sandro Bosco; Massimo Rossi; Kirchin A Miles; Rossella Di Miscio; Concetta Valentina Lombardo; Elisabetta Tamponi; Mario Piga; Carlo Catalano
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

4.  A Life-Saving Cancer: More on the Double Whammy.

Authors:  Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2016-04-01

Review 5.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

6.  In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: a new model in rats.

Authors:  S M Maksan; H Paulo; E Ryschich; C Kuntz; M M Gebhard; E Klar; J Schmidt
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

7.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

8.  Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan.

Authors:  Nestor F Esnaola; Nadeem Mirza; Gregory Y Lauwers; Iwao Ikai; Jean-Marc Regimbeau; Jacques Belghiti; Yoshio Yamaoka; Steven A Curley; Lee M Ellis; David M Nagorney; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

Review 9.  [Liver resections for primary liver malignancies. Personal results and analysis of the literature].

Authors:  J Zieren; H U Zieren; J M Müller
Journal:  Langenbecks Arch Chir       Date:  1994

10.  Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.

Authors:  B Ringe; R Pichlmayr; C Wittekind; G Tusch
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.